<DOC>
	<DOCNO>NCT00384631</DOCNO>
	<brief_summary>Several study confirm high level vascular endothelial growth factor ( VEGF ) eye neovascular glaucoma ( NVG ) . The role VEGF inhibitor regression neovascular disorder wet-type age-related macular degeneration diabetic macular edema describe . We aim evaluate effect three intravitreal injection bevacizumab ( Avastin ) 2.5 mg versus sham procedure treatment NVG . Outcome measure include intraocular pressure extent iris neovascularization . Both study arm receive conventional treatment NVG .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Neovascular Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical diagnosis NVG Vision less 20/200 age 1080 year Uncontrolled Blood Pressure History thromboembolism Congestive Heart Failure Renal Failure Pregnancy Lactation Active ocular periocular infection No light perception</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Neovascular</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>IOP</keyword>
</DOC>